Reviva Pharmaceuticals Holdings (RVPH) Stock Statistics & Valuation Metrics

Reviva Pharmaceuticals Holdings has a market cap or net worth of $5.12M. The enterprise value is -$20.54M.

Reviva Pharmaceuticals Holdings has 12,810,377 shares outstanding. The number of shares has decreased by -2.65% in one year.

Reviva Pharmaceuticals Holdings’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is >-0.01%.

The current PE Ratio of Reviva Pharmaceuticals Holdings is ―. Reviva Pharmaceuticals Holdings’s PEG ratio is 0.01.

In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0.00 and earned -19.86M in profits. Earnings per share was -5.48.

In the last 12 months, operating cash flow was -20.20M and capital expenditures 0.00, giving a free cash flow of -20.20M billion.

Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―

Reviva Pharmaceuticals Holdings upcoming earnings date is Aug 17, 2026, TBA (Confirmed).

Reviva Pharmaceuticals Holdings as a current ratio of 2.08, with Debt / Equity ratio of 1.33%

In the past 12 months, Reviva Pharmaceuticals Holdings has paid 18.89K in taxes.

Reviva Pharmaceuticals Holdings EV to EBITDA ratio is 707.52K, with an EV/FCF ratio of 570.53K.

Reviva Pharmaceuticals Holdings has $22.19M in cash and marketable securities with $231.27K in debt, giving a net cash position of $21.96M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Reviva Pharmaceuticals Holdings is $15.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy